Emtifovir is the combination of Emtricitabine and Tenofovir Disoproxil Fumarate. Tenofovir Disoproxil Fumarate is converted in-vivo to Tenofovir. Emtricitabine and Tenofovir exhibit inhibitory activity against HIV-1 reverse transcriptase enzyme.
Adult ≥18 yr: As tablet containing 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate: 1 tablet once daily. For patients with swallowing difficulties, tablet may be disintegrated in approx 100 ml of water, orange juice or grape juice and consumed immediately.
Recommended Dosing Interval-
CrCl ≥ 50 ml/min: Every 24-hour
CrCl 30-49 mL/min: Every 48-hour
CrCl < 30 mL/min: Should not be administered Routine monitoring of estimated creatinine clearance, serum phosphorus, urine glucose, and urine protein should be performed in all individuals with mild renal impairment. Pre-exposure Prophylaxis: Do not use Emtifovir for a Pre-Exposure Prophylaxis indication in HIV-1 uninfected individuals with estimated creatinine clearance below 60 mL/min.